CSHS WWW HOME | MS EXCHANGE LOG ON | PULSE ARCHIVES
Medical Staff Pulse is
a Publication of the Chief of Staff
Pharmacy Focus

New FDA Warning on Neupro (Rotigotine Transdermal System)

Schwarz Pharma has informed healthcare professionals and patients of the recall of Neupro, a transdermal delivery system worn on the skin and used to treat early stage Parkinson's disease, because of the formation of rotigotine crystals in the patches.

When the drug crystallizes, less of the drug is available to be absorbed through the skin and the efficacy of the product may vary.

Healthcare professionals should not initiate any new patients on Neupro and should begin to down-titrate all patients currently using the product per the guidelines in the product labeling. Patients should NOT abruptly discontinue therapy. Abrupt withdrawal of dopamine agonists has been associated with a syndrome resembling neuroleptic malignant syndrome or akinetic crises.